Close

AstraZeneca (AZN) Terminates Valeant's (VRX) Brodalumab Development Agreement for Europe

July 1, 2016 6:11 AM EDT Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its affiliate and AstraZeneca (NYSE: AZN) have amended Valeant's license for brodalumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login